2.90% of Eloxx Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Eloxx Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2023	Armistice Capital LLC	275,000	$1.32M	0.0%	N/A	10.000%
2/13/2023	American Financial Group Inc.	37,000	$67K	0.0%	-97.5%	1.705%
2/13/2023	Clal Insurance Enterprises Holdings Ltd	14,626	$27K	0.0%	-97.5%	0.674%
1/26/2023	Harel Insurance Investments & Financial Services Ltd.	29,410	$54K	0.0%	-97.5%	1.355%
7/25/2022	Silverarc Capital Management LLC	1,041,499	$0.28M	0.1%	-46.6%	1.202%
2/10/2022	B. Riley Wealth Management Inc.	48,500	$34K	0.0%	N/A	0.056%
2/7/2022	Harel Insurance Investments & Financial Services Ltd.	1,176,401	$0.83M	0.0%	N/A	1.364%
2/2/2022	Vanguard Capital Wealth Advisors	158,900	$0.11M	0.1%	-63.7%	0.184%
11/17/2021	Altium Capital Management LP	1,118,000	$1.82M	0.4%	+66.8%	1.296%
11/16/2021	Two Sigma Advisers LP	705,300	$1.15M	0.0%	+214.2%	0.818%
11/16/2021	Two Sigma Investments LP	314,874	$0.51M	0.0%	+195.7%	0.365%
11/15/2021	Natixis	103,900	$0.17M	0.0%	N/A	0.120%
11/12/2021	Geode Capital Management LLC	772,836	$1.26M	0.0%	+46.6%	0.897%
11/9/2021	Sawtooth Solutions LLC	16,201	$26K	0.0%	N/A	0.019%
11/9/2021	BlackRock Inc.	490,871	$0.80M	0.0%	+157.4%	0.569%
11/1/2021	Vanguard Capital Wealth Advisors	437,900	$0.46M	0.3%	+250.3%	0.508%
10/14/2021	Private Advisor Group LLC	32,510	$52K	0.0%	N/A	0.038%
8/17/2021	Millennium Management LLC	393,703	$0.78M	0.0%	N/A	0.823%
8/17/2021	Bridgeway Capital Management LLC	149,000	$0.30M	0.0%	-12.8%	0.311%
8/16/2021	LMR Partners LLP	14,435	$29K	0.0%	N/A	0.030%
8/16/2021	Cubist Systematic Strategies LLC	83,344	$0.17M	0.0%	N/A	0.174%
8/16/2021	Nantahala Capital Management LLC	2,266,287	$4.51M	0.1%	N/A	4.736%
8/16/2021	Occudo Quantitative Strategies LP	42,247	$84K	0.0%	N/A	0.088%
8/16/2021	Charles Schwab Investment Management Inc.	367,062	$0.73M	0.0%	+125.5%	0.767%
8/16/2021	State Street Corp	189,203	$0.38M	0.0%	-56.8%	0.395%
8/13/2021	Renaissance Technologies LLC	163,900	$0.33M	0.0%	N/A	0.342%
8/13/2021	Northern Trust Corp	136,872	$0.27M	0.0%	-53.2%	0.286%
8/13/2021	Altium Capital Management LP	670,118	$1.33M	0.3%	N/A	1.400%
8/13/2021	Geode Capital Management LLC	527,307	$1.05M	0.0%	+18.8%	1.102%
8/13/2021	Vanguard Group Inc.	3,055,517	$6.08M	0.0%	+156.2%	6.385%
8/12/2021	XTX Topco Ltd	46,884	$93K	0.0%	N/A	0.098%
8/12/2021	Ergoteles LLC	121,900	$0.24M	0.0%	N/A	0.255%
8/11/2021	Deutsche Bank AG	68,000	$0.14M	0.0%	+279.6%	0.142%
8/9/2021	Meeder Asset Management Inc.	20,457	$41K	0.0%	+242.3%	0.043%
8/3/2021	Victory Capital Management Inc.	12,359	$25K	0.0%	N/A	0.026%
7/28/2021	Vanguard Capital Wealth Advisors	125,000	$0.25M	0.2%	N/A	0.261%
5/13/2021	Barclays PLC	22,278	$74K	0.0%	+159.0%	0.047%
5/12/2021	Northern Trust Corp	292,217	$0.97M	0.0%	-9.3%	0.611%
5/12/2021	Geode Capital Management LLC	443,810	$1.47M	0.0%	+5.7%	0.927%
5/7/2021	BlackRock Inc.	1,529,325	$5.08M	0.0%	+1.7%	3.803%
2/19/2021	JPMorgan Chase & Co.	69,725	$0.28M	0.0%	+599.8%	0.174%
2/16/2021	Charles Schwab Investment Management Inc.	162,804	$0.65M	0.0%	+4.3%	0.405%
2/11/2021	Northern Trust Corp	322,099	$1.28M	0.0%	-0.8%	0.802%
2/11/2021	Barclays PLC	8,601	$34K	0.0%	-29.1%	0.021%
2/10/2021	Rhumbline Advisers	33,364	$0.13M	0.0%	+20.0%	0.083%
2/10/2021	Renaissance Technologies LLC	39,733	$0.16M	0.0%	-33.3%	0.099%
2/9/2021	Wells Fargo & Company MN	37,814	$0.15M	0.0%	+31.2%	0.094%
2/9/2021	Bank of New York Mellon Corp	71,568	$0.29M	0.0%	-4.5%	0.178%
2/5/2021	BlackRock Inc.	1,503,924	$5.99M	0.0%	+0.6%	3.745%
11/10/2020	State Street Corp	445,336	$1.17M	0.0%	+2.8%	1.110%
11/6/2020	BlackRock Inc.	1,494,861	$3.93M	0.0%	-1.1%	3.724%

Data available starting January 2016

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: N/A

50 Day Range

MA: $0.29

$0.00

$0.70

52 Week Range

Now: N/A

Volume

1,530 shs

Average Volume

2,005 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.63

#1 Crypto of 2024

From True Market Insiders | Ad

#1 FREE Crypto for 2024